Pilot Study of NKG2D CAR-T in Treating Patients With Recurrent Glioblastoma
This is a pilot phase I study to evaluate the safety and efficacy of NKG2D CAR-T cell therapy in patients with relapsed and/or refractory glioblastoma
Recurrent Glioblastoma
BIOLOGICAL: NKG2D CAR-T
Number of Participants who experience a Dose-Limiting Toxicity (DLT), Defined as the dose safely administered Intratumoral for the treatment of patients with GBM, 2 years
Overall Response Rate, Defined as the proportion of subjects with overall response of either complete response (CR) or partial response (PR), 1 year|Progression-free survival, Defined as date of the first NKG2D CAR-T infusion to the date of disease progression per RANO Response Criteria or death, 1 year
This is a pilot phase I study to evaluate the safety and efficacy of NKG2D CAR-T cell therapy in patients with relapsed and/or refractory glioblastoma